Recently, the Hurun Research Institute—one of the world’s most influential authorities on global entrepreneurship rankings—released the Hurun Future Unicorns: Global Gazelles Index 2025 in Beijing E-Town. The index identifies 819 high-growth companies founded after 2000 that are most likely to achieve unicorn status, defined as a valuation of USD 1 billion, within the next three years (by the end of 2028). Among them, 278 companies are based in China, including 46 biotechnology enterprises among which 13 companies are from Guangzhou.

China’s gazelle companies are primarily concentrated in biotechnology and semiconductors, which together account for approximately 30% of the total Chinese cohort. Creative Biosciences was successfully selected for the list in recognition of its sustained innovation capabilities and strong market performance in the field of early cancer screening. This distinction underscores the company’s achievements and potential in technological innovation, market expansion, and long-term growth, as acknowledged by a globally respected independent institution.

About the Hurun Future Unicorns: Global Gazelles Index

The Hurun Future Unicorns: Global Gazelles Index 2025 focuses on innovative companies founded after 2000 that are projected to reach a valuation of USD 1 billion by the end of 2028. The valuation cut-off date for this edition is October 31, 2025. The index spans 43 countries and 220 cities worldwide, highlighting future stars with exceptional growth momentum and disruptive potential across sectors such as technology and biopharmaceuticals.

Advancing Early Cancer Screening to Protect Lives

Since its inception, Creative Biosciences has remained dedicated to the research, development, and clinical translation of early screening technologies for high-incidence cancers. Through continuous innovation, the company aims to improve the accessibility and precision of early cancer detection, supporting earlier intervention and more effective cancer prevention strategies. Being named to the Hurun Global Gazelles Index is not only an affirmation of Creative Biosciences’ current accomplishments, but also a strong endorsement of its future prospects. Looking ahead, the company will continue to uphold its mission of safeguarding health through science and earning trust through professionalism. Creative Biosciences will further expand its product portfolio and application scenarios, while accelerating its global market presence. We look forward to deepening collaboration with partners worldwide to jointly advance early cancer screening and contribute Chinese innovation to global health.